The performance of companies tied to flagship drugs like Viagra presents a complex investment picture. While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial profits , the loss of exclusivity in key regions has introduced substantial uncertainty . Investors are now grappling with the impact of rival